KESTRA MEDICAL TECHNOLOGIES
KMTSNASDAQTrading Snapshot
- Day Range
- $28.29 – $28.78
- 52-Week Range
- $17.34 – $30.00
- Volume
- $3.57B
- Avg Volume
- $4.50B
- Shares Outstanding
- 58.6M
- Next Earnings
- Dec 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $95M
- Last Q Revenue
- $31M
- P/E Ratio
- —
- P/S Ratio
- 15.7x
- EPS (TTM)
- $-2.67
- Dividend Yield
- —
- Dilution (1yr)
- +14.0%
Why Investors Own KMTS
- ✓High-growth profile — revenue up +54.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 38% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
KESTRA MEDICAL TECHNOLOGIES
KMTS
StockOtter · stockotter.spaceAbout KESTRA MEDICAL TECHNOLOGIES
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Kestra Medical: Strong Scaling Story, But Profitability Still On The Horizon
Kestra Medical Technologies is transitioning into a high-growth, high-quality medtech platform with 60% YoY revenue growth and expanding gross margins. KMTS targets mid-70s gross margins within 2–3 years, driven by impro
Kestra Medical Technologies (NASDAQ:KMTS) Shares Gap Down After Earnings Miss
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS - Get Free Report)'s share price gapped down before the market opened on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $24.06
Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures falling around 200 points on Tuesday.
Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue Estimates
Kestra Medical Technologies, Ltd. (KMTS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.61.
Kestra Medical Technologies Q1 Earnings Call Highlights
Kestra Medical Technologies NASDAQ: KMTS reported first-quarter fiscal 2027 revenue of $31 million, with President and Chief Executive Officer Brian Webster saying revenue rose 60% from a year earlier and advanced sequen